Loading...
XPARADOC
Market cap96mUSD
Dec 24, Last price  
5.98EUR
1D
1.01%
1Q
5.84%
Jan 2017
-90.20%
IPO
-60.50%
Name

Adocia SA

Chart & Performance

D1W1MN
XPAR:ADOC chart
P/E
P/S
43.00
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.79%
Rev. gr., 5y
-46.13%
Revenues
2m
-81.22%
111,0001,551,0003,996,0005,589,000704,00036,936,00022,488,00019,469,00047,389,0002,143,000841,0001,444,00011,447,0002,150,000
Net income
-21m
L+206.65%
-4,731,000-6,454,000-5,995,000-4,293,000-20,715,00012,553,000-7,892,000-8,551,0007,615,000-18,603,000-23,324,000-26,308,000-6,901,000-21,162,000
CFO
-5m
L-66.99%
-4,956,000-6,217,000919,000-10,796,00030,561,000-6,216,000-13,138,000-22,227,0006,313,000-9,655,000-21,854,000-19,234,000-14,995,000-4,950,000
Earnings
Apr 22, 2025

Profile

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.
IPO date
Feb 20, 2012
Employees
96
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,150
-81.22%
11,447
692.73%
1,444
71.70%
Cost of revenue
6,244
27,737
21,280
Unusual Expense (Income)
NOPBT
(4,094)
(16,290)
(19,836)
NOPBT Margin
Operating Taxes
2
476
3,554
Tax Rate
NOPAT
(4,096)
(16,766)
(23,390)
Net income
(21,162)
206.65%
(6,901)
-73.77%
(26,308)
12.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,868
1,042
BB yield
-6.15%
-1.82%
Debt
Debt current
2,427
15,671
16,194
Long-term debt
18,612
24,274
18,285
Deferred revenue
309
Other long-term liabilities
791
967
1,830
Net debt
8,078
21,054
19,213
Cash flow
Cash from operating activities
(4,950)
(14,995)
(19,234)
CAPEX
(156)
(153)
(361)
Cash from investing activities
(138)
21,864
(361)
Cash from financing activities
629
(4,611)
6,644
FCF
(4,408)
(18,651)
(15,201)
Balance
Cash
12,961
17,422
15,163
Long term investments
1,469
103
Excess cash
12,854
18,319
15,194
Stockholders' equity
(25,189)
(6,028)
(22,027)
Invested Capital
32,764
27,030
44,604
ROIC
ROCE
EV
Common stock shares outstanding
11,081
8,032
7,058
Price
11.54
190.68%
3.97
-50.99%
8.10
-2.41%
Market cap
127,870
301.03%
31,885
-44.22%
57,167
-1.23%
EV
135,948
152,905
171,484
EBITDA
(3,595)
(15,733)
(18,678)
EV/EBITDA
Interest
1,308
2,859
2,249
Interest/NOPBT